Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial

Patients with newly resected stage II melanoma (n = 104) were randomized to receive adjuvant vitamin D3 (100,000 IU every 50 days) or placebo for 3 years to investigate vitamin D3 protective effects on developing a recurrent disease. Median age at diagnosis was 50 years, and 43% of the patients were...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nutrients 2021-06, Vol.13 (6), p.1931
Hauptverfasser: Johansson, Harriet, Spadola, Giuseppe, Tosti, Giulio, Mandalà, Mario, Minisini, Alessandro M, Queirolo, Paola, Aristarco, Valentina, Baldini, Federica, Cocorocchio, Emilia, Albertazzi, Elena, Zichichi, Leonardo, Cinieri, Saverio, Jemos, Costantino, Mazzarol, Giovanni, Gnagnarella, Patrizia, Macis, Debora, Tedeschi, Ines, Salè, Emanuela Omodeo, Stucci, Luigia Stefania, Bonanni, Bernardo, Testori, Alessandro, Pennacchioli, Elisabetta, Ferrucci, Pier Francesco, Gandini, Sara
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Patients with newly resected stage II melanoma (n = 104) were randomized to receive adjuvant vitamin D3 (100,000 IU every 50 days) or placebo for 3 years to investigate vitamin D3 protective effects on developing a recurrent disease. Median age at diagnosis was 50 years, and 43% of the patients were female. Median serum 25-hydroxy vitamin D (25OHD) level at baseline was 18 ng/mL, interquartile range (IQ) was 13–24 ng/mL, and 80% of the patients had insufficient vitamin D levels. We observed pronounced increases in 25OHD levels after 4 months in the active arm (median 32.9 ng/mL; IQ range 25.9–38.4) against placebo (median 19.05 ng/mL; IQ range 13.0–25.9), constantly rising during treatment. Remarkably, patients with low Breslow score (
ISSN:2072-6643
2072-6643
DOI:10.3390/nu13061931